3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 3
2
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
156
Lung Neoplasms
57
Uterine Cervical Neoplasms
53
Squamous Cell Carcinoma of Head and Neck
52
Nasopharyngeal Carcinoma
51
Head and Neck Neoplasms
47
Stomach Neoplasms
37
Parkinson Disease 4, Autosomal Dominant Lewy Body
35
Esophageal Neoplasms
31
Urinary Bladder Neoplasms
26
Small Cell Lung Carcinoma
21
Esophageal Squamous Cell Carcinoma
21
Ovarian Neoplasms
19
Carcinoma
14
Neoplasm Metastasis
13
Cholangiocarcinoma
13
Recurrence
11
Neuroblastoma
11
Nasopharyngeal Neoplasms
11
Carcinoma, Ovarian Epithelial
11
Biliary Tract Neoplasms
11
Adenocarcinoma Of Esophagus
11
Neoplasms
10
Gallbladder Neoplasms
10
Carcinoma, Transitional Cell
10
Testicular Neoplasms
9
Adenocarcinoma of Lung
9
Teratoma
8
Oropharyngeal Neoplasms
8
Endometrial Neoplasms
8
Interventions
Etoposide
3
Cisplatin
2
Carboplatin
2
belotecan
1
atezolizumab
1
RRx-001
1
PM 01183
1
EC regimen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Small Cell
×
Cisplatin
×
Clear all
NCT03699956
2024-03-26
REPLATINUM
EpicentRx, Inc.
Phase 3
Terminated
18 enrolled
NCT00826644
2021-08-09
COMBAT
Chonnam National University Hospital
Phase 3
Completed
147 enrolled